Stock IdeasStrong Buy StocksStrong Buy Stocks from Top Wall Street AnalystsLatest stocks with a Strong Buy rating from the top performing 25% of analysts tracked by WallStreetZen
Stock IdeasStrong Buy Stocks
| Analyst / Firm | Company | Price | Rating | Price Target | Upside/Downside | Date |
|---|---|---|---|---|---|---|
Guardant Health IncGH | $170.77 | Strong Buy | $190.00 | +11.26% | 18 hours ago | |
Analyst RankingTop 1% #42 out of 5313 analysts Average Return+63.92% Win Rate55%108 out of 198 Risk vs RewardPoor Good Analyst ColorBTIG's Mark Massaro raised their price target on Guardant Health (NASDAQ: GH) by 18.8% from $160 to $190 on 2026/07/01. The analyst maintained their Strong Buy rating on the stock. Noting that the stock price is rising on the back of a surprising positive coverage determination from UnitedHealth Group for the GH Shield blood test, Massasro called the news a "huge" derisking event for Guardant Health's screening business. The analyst added that the timing of the coverage was 1 to 2 years before BTIG expected and predicted that other commercial payors will follow suit over the coming quarters. | ||||||
Tesla IncTSLA | $800.00 | Strong Buy | $850.00 | +6.25% | a day ago | |
Upgrade to Premium to View MoreStrong buys: Upgrade to Premium to view the rest of today's Strong Buy stocks from Wall Street's top analysts Already have access to Premium? Sign In | ||||||
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.